APT: adjuvant paclitaxel and trastuzumab for small, node-negative HER2-positive breast cancer
Twelve weeks of paclitaxel with a year of trastuzumab, and no anthracycline, was enough to keep more than 98 percent of women with small node-negative HER2-positive breast cancers free of recurrence at three years.
Overview
Single-arm phase 2 study of 406 patients with node-negative HER2-positive breast cancer up to 3 cm treated with weekly paclitaxel for 12 weeks plus trastuzumab for one year.
Three-year invasive disease-free survival was 98.7 percent, with only two distant recurrences, and seven-year follow-up confirmed durable results with minimal cardiac toxicity. It established a de-escalated regimen for stage I disease.
- Three-year invasive disease-free survival 98.7 percent.
- Seven-year disease-free survival 93 percent with 97.5 percent recurrence-free interval.
Women with small HER2-positive tumours can avoid anthracyclines and multi-agent chemotherapy; the APT regimen is a guideline standard for stage I HER2-positive disease.
- Non-randomised; the excellent outcomes may partly reflect a favourable population.
- Most tumours were under 2 cm and hormone receptor-positive.
Similar pages
not linked directly; found by shared links- Key paperAPHINITY: adjuvant pertuzumab added to trastuzumab and chemotherapy in early HER2-positive breast cancer
Shares Early HER2-positive breast cancer, Trastuzumab, New England Journal of Medicine.
- TrialA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- TrialATEMPT
- TrialAPT (adjuvant paclitaxel-trastuzumab)
- Key paperDESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer
- TrialA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea
- Key paperHER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases
- TermTrastuzumab cardiotoxicity